Endothelial t-PA release is impaired in overweight and obese adults but can be improved with regular aerobic exercise

Gary P. Van Guilder,1 Greta L. Hoetzer,1 Derek T. Smith,1 Heather M. Irmiger,1 Jared J. Greiner,1 Brian L. Stauffer,1,2 and Christopher A. DeSouza1,2

1Integrative Vascular Biology Laboratory, Department of Integrative Physiology University of Colorado, Boulder; and 2Department of Medicine, University of Colorado, Health Sciences Center, Denver, Colorado

Submitted 22 February 2005 ; accepted in final form 22 June 2005


    ABSTRACT
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Endothelial release of tissue-type plasminogen activator (t-PA) regulates fibrinolysis and is considered to be a primary endogenous defense mechanism against thrombosis. Adiposity is associated with an increased risk of atherothrombotic events. We determined the influence of overweight and obesity on the capacity of the vascular endothelium to release t-PA and the effects of regular aerobic exercise on endothelial t-PA release in previously sedentary overweight and obese adults. First, we studied 66 sedentary adults: 28 normal-weight (BMI <25 kg/m2); 22 overweight (BMI ≥25 and <30 kg/m2); and 16 obese (BMI ≥30 kg/m2). Net endothelial t-PA release was determined in vivo in response to intrabrachial infusions of bradykinin (BK) and sodium nitroprusside. Second, we studied 17 overweight and obese adults who completed a 3-mo aerobic exercise intervention. Net release of t-PA in response to BK was ~45% lower (P < 0.01) in overweight (from 0.1 ± 0.4 to 41.7 ± 4.9 ng·100 ml tissue–1·min–1) and obese (–0.1 ± 0.6 to 47.7 ± 5.2 ng·100 ml tissue–1·min–1) compared with normal-weight (0.1 ± 0.8 to 77.5 ± 6.7 ng·100 ml tissue–1·min–1) adults. There was no difference in t-PA release between the overweight and obese groups. Exercise training significantly increased t-PA release capacity in overweight and obese adults (from –0.3 ± 0.5 to 37.1 ± 4.9 ng·100 ml tissue–1·min–1 before training vs. 1.0 ± 0.9 to 65.4 ± 6.3 ng·100 ml tissue–1·min–1 after training) to levels comparable with those of their normal-weight peers. These results indicate that overweight and obesity are associated with profound endothelial fibrinolytic dysfunction. Importantly, however, regular aerobic exercise can increase the capacity of the endothelium to release t-PA in this at-risk population.

endothelium; fibrinolysis; tissue-type plasminogen activator


RECENT ESTIMATES INDICATE that over 60% of the adult population in the United States is either overweight or obese (21). Moreover, the incidence of overweight and obesity is highest in middle-aged and older adults and is thought to contribute to the increased risk of coronary artery disease, cerebrovascular disease, and atherothrombotic events in this segment of the population (37, 39, 40).

It is now well accepted that endothelial dysfunction plays an important role in the initiation and progression of atherosclerosis (5, 45). A potential mechanism underlying the heightened atherothrombotic risk with obesity is impaired endothelial control of fibrinolysis. Endothelial cells are the principal site of synthesis and release of tissue-type plasminogen activator (t-PA), the key enzyme in initiating an endogenous fibrinolytic response, due to its ability to preferentially activate plasminogen on the surface of developing thrombi (15). Experimental and clinical data indicate that it is the capacity of the endothelium to release t-PA rapidly and acutely from intracellular storage pools, and not circulating plasma fibrinolytic concentrations, that determines the efficacy of endogenous fibrinolysis (42, 49a). Indeed, the thrombolytic potential of t-PA is greatest if it is readily available and incorporated during, rather than after, thrombus formation (4, 22). Moreover, diminished endothelial t-PA release has been linked with accelerated thrombogenesis (6, 10). Currently, it is unknown whether the capacity of the endothelium to acutely release t-PA is compromised in overweight and obese adult humans. If so, this may contribute mechanistically to their increased risk of thrombosis.

Regular aerobic exercise is associated with a reduction in cardiovascular events in overweight and obese adults, independent of weight loss (2). One of the possible mechanisms by which regular aerobic exercise confers this cardioprotection is via its availing effects on endothelial function. Indeed, improved endothelial vasomotor function has been linked to a reduction in cardiovascular events (32). Exercise-induced enhancement in the capacity of the endothelium to release t-PA might also contribute to the reduced cardiovascular risk observed in physically active overweight adults (32).

Accordingly, we tested the following hypotheses: 1) the capacity of the vascular endothelium to acutely release t-PA is impaired in overweight and obese adults; and 2) regular aerobic exercise training would improve endothelial t-PA release in previously sedentary overweight and obese adults. To address these hypotheses, we employed both cross-sectional and intervention study designs. First, we used a cross-sectional model to determine the influence of overweight and obesity on the capacity of the endothelium to release t-PA. We then performed an intervention study to determine the effects of moderate aerobic exercise training on endothelial t-PA release rates in sedentary overweight and obese adults.


    METHODS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Subjects

Cross-sectional study. Sixty-six sedentary adults (37 males, 29 females) were studied: 28 normal-weight (BMI <25 kg/m2); 22 overweight (BMI ≥25 and <30 kg/m2); and 16 obese (BMI ≥30 kg/m2) adults. All subjects were sedentary and had not participated in a regular aerobic exercise program for ≥2 yr before the start of the study. Subjects were excluded from the study if they presented a history or evidence of hepatic, renal, or hematological disease; peripheral vascular disease; stroke; diabetes [fasting plasma glucose >7.0 mmol/l (1)]; dyslipoproteinemia [total cholesterol ≥6.0 mmol/l, LDL-cholesterol ≥4.5 mmol/l, triglycerides ≥2.5 mmol/l (19)]; and hypertension [BP ≥140/90 mmHg (9)]. All subjects were screened for clinical evidence of coronary artery disease with resting and maximal exercise electrocardiograms and blood pressure. None of the subjects smoked or were taking medication, including vitamins. All of the women were ≥1 yr postmenopausal (mean: 7 ± 1 yr) and had never taken or had discontinued use of hormone replacement therapy ≥1 yr before the start of the study. Before participation, all of the subjects had the research study and its potential risks and benefits explained fully before providing written informed consent. This study was approved by the Human Research Committee of the University of Colorado at Boulder.

Intervention study. Seventeen of the 38 overweight and obese adults (11 male, 6 female) who participated in the cross-sectional study enrolled in a 3-mo aerobic exercise training program. All baseline measurements were subsequently repeated in these subjects after the exercise intervention.

Measurements

Body composition. Body mass was measured to the nearest 0.1 kg using a medical beam balance (Detecto, Webb City, MO). Percent body fat was determined by dual-energy X-ray absorptiometry (Lunar Radiation, Madison, WI). BMI was calculated as weight (kg) divided by height (m) squared. Minimal waist circumference was measured according to previously published guidelines (33).

Treadmill exercise test. To assess aerobic fitness, subjects performed incremental treadmill exercise using a modified Balke protocol as previously described (11). Maximal oxygen consumption (O2 max) was measured using online computer-assisted open-circuit spirometry. In addition, heart rate and rating of perceived exertion were measured throughout exercise, and total exercise time to exhaustion was recorded.

Metabolic measurements. Fasting plasma lipid and lipoprotein, glucose, and insulin concentrations were determined using standard techniques by the clinical laboratory affiliated with the General Clinical Research Center. Insulin resistance was estimated using the homeostasis model assessment (HOMA-IR) derived from fasting glucose and insulin concentrations (35).

Markers of inflammation. Fasting plasma concentrations of C-reactive protein (CRP), interleukin (IL)-6, IL-18, and tumor necrosis factor (TNF)-{alpha}, were determined by ELISA (ALPCO Diagnostics, R&D Systems). Inter- and intra-assay variability for all assays were <7 and <8%, respectively.

Intra-Arterial Fibrinolytic Protocol.

All measurements were performed in a temperature-controlled room between 7 and 10 AM after a 12-h overnight fast, as previously described by our laboratory (24, 48). Briefly, an intravenous catheter was placed in a deep antecubital vein of the nondominant arm. Thereafter, a 5-cm, 20-gauge catheter was introduced into the brachial artery of the same arm under local anesthesia (1% lidocaine). Forearm blood flow (FBF) was measured using strain-gauge venous occlusion plethysmography (D. E. Hokanson, Bellevue, WA) and presented as milliliters per 100 milliliters forearm volume per minute. After the measurement of resting blood flow for 5 min, bradykinin was infused intra-arterially at rates of 12.5, 25, and 50 ng·100 ml tissue–1·min–1 and sodium nitroprusside at 1.0, 2.0, and 4.0 µg·100 ml tissue–1·min–1 for 5 min at each dose, as previously described (24). To avoid an order effect, the sequence of drug administration was randomized. Forearm volume was determined by the water displacement method.

Net endothelial release of t-PA antigen and plasminogen activator inhibitor-1 (PAI-1) antigen in response to bradykinin and sodium nitroprusside was calculated according to Jern et al. (27) using the following equation:

where CV and CA represent the concentration in the vein and artery, respectively. For both t-PA and PAI-1, a positive difference indicated a net release and a negative difference net uptake. Arterial and venous blood samples were collected simultaneously at baseline and at the end of each drug dose. t-PA and PAI-1 antigen concentrations were determined by enzyme immunoassay. Hematocrit was measured in triplicate using the standard microhematocrit technique and corrected for trapped plasma volume within the trapped erythrocytes (8). The total amount of t-PA antigen released across the forearm in response to bradykinin was calculated as the total area under each curve above baseline using a trapezoidal model. To avoid confounding effects from potential infection/inflammation-associated fibrinolytic changes, all subjects were free of recent infection/inflammation (<2 wk), as determined by questionnaire (34).

Exercise Intervention.

The 3-mo home-based aerobic exercise training program employed in the present study has been described previously by our laboratory (11). Briefly, after completion of baseline measurements, subjects underwent a supervised orientation, after which they exercised on their own. Subjects were asked to exercise 5–7 days/wk, 40–50 min/day, at 60–75% of their individual maximum heart rate, determined during maximal exercise testing. Most subjects walked, but some integrated jogging into their exercise session as their fitness improved, to maintain their heart rate within the prescribed range. Compliance with the exercise program was documented every 2 wk using data downloaded directly from heart rate monitors (Polar Electro, Woodbury, NY) and from exercise logs.

Statistical Analysis.

Differences in subject baseline characteristics and area under the curve data were determined by between-groups analysis of variance (ANOVA). Group differences in FBF and endothelial t-PA and PAI-1 antigen release in response to bradykinin and sodium nitroprusside were determined by repeated-measures ANOVA. When indicated by a significant F value, a post hoc test using the Newman-Keuls method was performed to identify differences among the groups. Relationships between variables of interest were assessed by means of Pearson's correlation coefficient and linear regression analysis. Changes in the dependent variables resulting from the exercise intervention were assessed by repeated-measures ANOVA. Importantly, there were no significant gender interactions in any of the key outcome variables; therefore, the data were pooled and presented together. Because of the skewed distribution of plasma CRP concentrations, the data were log-transformed to satisfy basic assumptions for parametric testing. However, per joint American College of Cardiology and Centers for Disease Control recommendations (43), the absolute values for CRP are presented to facilitate clinical interpretation. All data are expressed as means ± SE. Statistical significance was set a priori at P < 0.05.


    RESULTS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Cross-Sectional Study

Table 1 presents selected subject characteristics. By design, body mass, BMI, and waist circumference were higher (P < 0.01) in the overweight and obese subjects compared with normal-weight controls. There were no differences in age, resting blood pressure, O2 max, and plasma lipid and lipoprotein concentrations between the groups. Although within clinically normal levels, plasma glucose and insulin concentrations, as well as HOMA-IR levels, were highest in the obese group. Plasma concentrations of inflammatory markers are shown in Table 2. Circulating CRP and IL-18 levels were higher (P < 0.05) in the overweight and obese compared with normal-weight subjects.


View this table:
[in this window]
[in a new window]
 
Table 1. Selected subject characteristics

 

View this table:
[in this window]
[in a new window]
 
Table 2. Plasma concentrations of inflammatory markers in the cross-sectional and exercise intervention studies

 
FBF responses to bradykinin were significantly lower (~20%) in the overweight and obese compared with normal-weight subjects. There were no significant differences among the groups in the forearm vasodilator responses to sodium nitroprusside (Table 3).


View this table:
[in this window]
[in a new window]
 
Table 3. FBF responses to bradykinin and sodium nitroprusside in the cross-sectional and exercise intervention studies

 
Basal endothelial t-PA antigen release was not significantly different among the groups. However, the capacity of the endothelium to release t-PA in response to bradykinin stimulation was significantly blunted in the overweight and obese adults (Fig. 1). Net release of t-PA antigen was ~45% less (P < 0.01) in the overweight (from 0.1 ± 0.4 to 41.7 ± 4.9 ng·100 ml tissue–1·min–1) and obese (from –0.1 ± 0.6 to 47.7 ± 5.2 ng·100 ml tissue–1·min–1) compared with normal-weight (from 0.1 ± 0.8 to 77.5 ± 6.7 ng·100 ml tissue–1·min–1) subjects. As a result, the total amount of t-PA antigen released (area under the curve) was much lower (P < 0.01) in the overweight (210 ± 23 ng/100 ml tissue) and obese (224 ± 22 ng/100 ml tissue) than normal-weight adults (395 ± 34 ng/100 ml tissue; Fig. 3). There were no significant differences in either the rate or total amount of t-PA release between the overweight and obese adults. Infusion of sodium nitroprusside did not stimulate significant increases in t-PA release in either the normal-weight (–0.6 ± 0.5 to 3.7 ± 3.9 ng·100 ml tissue–1·min–1), overweight (from 1.7 ± 1.1 to 1.8 ± 2.8 ng·100 ml tissue–1·min–1), or obese (from –0.1 ± 0.4 to 2.1 ± 2.3 ng·100 ml tissue–1·min–1) groups. Of note, neither bradykinin nor sodium nitroprusside elicited consistent or significant changes in PAI-1 antigen release in any of the groups. Marginal release was observed at the highest dose of bradykinin in the normal-weight (3.8 ± 3.7 ng·100 ml tissue–1·min–1), overweight (6.0 ± 2.4 ng·100 ml tissue–1·min–1), and obese (1.3 ± 3.9 ng·100 ml tissue–1·min–1) groups.



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1. Net release rate and total amount of tissue-type plasminogen activator (t-PA) antigen released (area under the curve) across the forearm in response to bradykinin in normal-weight, overweight, and obese adults. Values are means ± SE; *P < 0.05 vs. normal weight.

 
In the overall study population, the total amount of t-PA antigen released in response to bradykinin was significantly related to body mass (r = –0.40), percent fat (r = –0.29), BMI (r = –0.47), waist circumference (r = –0.28), plasma insulin (r = –0.36), plasma glucose (r = –0.55), HOMA-IR (r = –0.39), and IL-18 (r = –0.29).

Exercise Intervention Study

All 17 overweight and obese adults (age 57 ± 1 yr) completed the 3-mo exercise intervention study. Subjects exercised an average of 5.0 ± 0.3 days/wk for 44 ± 2 min/day at an intensity of 68 ± 1% of maximal heart rate. There were no significant changes in body mass, adiposity, heart rate at rest, arterial blood pressure, O2 max, plasma cholesterol, glucose or insulin concentrations, and HOMA-IR levels (Table 4). However, aerobic exercise training increased exercise time to exhaustion by ~20% (P < 0.01) and significantly decreased heart rate and ratings of perceived exertion at the same absolute submaximal level of exercise (~70% of baseline O2 max). Plasma concentrations of CRP, IL-6, IL-18, and TNF-{alpha} were not affected by exercise training (Table 2). In addition, FBF responses to bradykinin were higher but not significantly different after exercise training (Table 3).


View this table:
[in this window]
[in a new window]
 
Table 4. Selected subject characteristics of the exercise intervention study

 
Basal release rates of t-PA antigen did not significantly change with exercise training. However, net endothelial t-PA release rates in response to bradykinin were markedly higher (P < 0.01) after (from 1.0 ± 0.9 to 65.4 ± 6.3 ng·100 ml tissue–1·min–1) than before (–0.3 ± 0.5 to 37.1 ± 4.9 ng·100 ml tissue–1·min–1) exercise training. As a result, the total amount of t-PA antigen released (area under the curve) to bradykinin increased ~55% (from 208 ± 21 to 320 ± 31 ng/100 ml tissue, P < 0.01) with the exercise intervention (Fig. 2). There was no change in t-PA antigen release to sodium nitroprusside in response to exercise. Moreover, net release rates of PAI-1 antigen were not significantly different after exercise training. There were no significant relations observed between metabolic and inflammatory factors and the exercise-induced improvement in endothelial t-PA release.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2. Net release rate and total amount of t-PA antigen released across the forearm in response to bradykinin before and after 3 mo of aerobic exercise training. Values are means ± SE; *P < 0.05 vs. before training.

 

    DISCUSSION
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
The primary new findings of the present study are that 1) the capacity of the endothelium to release t-PA is blunted in middle-aged overweight and obese adults compared with their normal-weight peers; and 2) moderate aerobic exercise training, independently of weight loss, can improve the ability of the endothelium to release t-PA in previously sedentary overweight and obese adults. Endothelial fibrinolytic dysfunction may underlie the increased risk of thrombotic events associated with overweight and obesity. Importantly, however, this critical aspect of endothelial function can be improved in overweight and obese adults with regular aerobic exercise.

Overweight and obesity have been associated with increased cardiovascular morbidity and mortality (39, 40) resulting from atherothrombotic events. Indeed, overweight persons demonstrate accelerated atherosclerosis (36) and increased rates of myocardial infarction and stroke (40). In addition, excess adiposity has been linked to an increased risk of recurrent coronary events after an acute myocardial infarction (46, 50). The mechanisms underlying this thrombotic tendency are not completely understood. Much attention has been focused on the effects of adiposity on the fibrinolytic system, specifically differences in plasma concentrations of t-PA antigen and PAI-1 antigen in obese and normal-weight adults (17, 31, 47). However, systemic fibrinolytic concentrations provide an indirect, nonspecific, and in some cases misleading assessment of vascular fibrinolytic potential (26, 27). Plasma concentrations of t-PA and PAI-1 are highly dependent on the rate of t-PA/PAI-1 complex formation and, in turn, hepatic clearance (41). Moreover, we (23, 48) and others (27) have demonstrated that circulating t-PA and PAI-1 concentrations do not reflect the capacity of the endothelium to acutely release t-PA, the primary determinant of endogenous fibrinolytic activity.

The results of the present study demonstrate, for the first time, that the ability of the endothelium to release t-PA is markedly reduced in both overweight and obese adults. Both the rate and total amount of t-PA antigen released from the endothelium in response to bradykinin were ~50% lower in the overweight and obese adults compared with normal-weight controls of similar age. This loss in endothelial fibrinolytic function may have important clinical consequences. Indeed, the ability of endothelial cells to release t-PA is a vital defense mechanism against thrombosis; disruption of this process is considered to be an important antecedent to atherothrombotic disease (38, 41). For example, in animal models, t-PA-deficient mice demonstrate accelerated atherosclerotic fibrin deposition and extensive myocardial tissue necrosis (6, 10). In humans, reduced endothelial t-PA release rates have been linked to increased atheromatous plaque in cigarette smokers and myocardial infarctions in patients with acute coronary syndromes (25). Thus impaired endothelial release of t-PA may be an important factor underlying the prothrombotic state associated with overweight and obesity.

The mechanisms responsible for impaired endothelial t-PA release in overweight and obese adults are not clear. Although the FBF responses to bradykinin were significantly lower in the overweight and obese subjects compared with normal-weight controls, it is unlikely that the overweight/obesity-related differences in endothelial t-PA release were a blood flow-related phenomenon. Consistent with previous studies (24, 27, 48) we observed no significant effect of sodium nitroprusside on t-PA antigen release across the forearm despite a marked increase in limb blood flow in each group. In addition, we observed no correlation between bradykinin-induced changes in blood flow and t-PA release in either the overweight, obese, or normal-weight groups. The lack of differences in PAI-1 antigen release among the groups in response to bradykinin rules out the potential confounding effects of t-PA-PAI-1 complex formation. It has been suggested that increased inflammatory burden may contribute to the heightened risk of atherothrombosis with obesity (16, 52). Indeed, inflammatory mediators such as CRP, IL-6, and IL-18 have been linked to arterial thrombogenesis (3, 51). Although the overweight and obese subjects in the present study demonstrated significantly higher plasma concentrations of CRP, IL-18, and TNF-{alpha} compared with the normal-weight controls, only a weak, albeit significant, relation (r = –0.29) was observed with IL-18 and endothelial t-PA release. CRP, IL-6, and TNF-{alpha} were not associated with t-PA release. On the basis of these correlative findings, it would be unreasonable to dismiss the possibility that local inflammatory processes at the vascular wall might adversely affect endothelial function. However, the results of the present study indicate that impaired endothelial t-PA release in overweight and obese adults is largely unrelated to circulating inflammatory proteins. It is possible that overweight/obesity-related increases in oxidative stress may contribute to diminished endothelial t-PA release. Ex vivo studies have shown that oxidative stress not only inhibits t-PA release from cultured endothelial cells but also damages the fibrin-binding affinity of t-PA reducing its thrombolytic capacity (20, 30). In vivo, oxidative stress has been linked to impaired endothelial vasodilator function in overweight adults (44) and might also negatively impact endothelial t-PA release. We are currently investigating the effects of oxidative stress on endothelial t-PA release in obese adults.

It is important to note that the overweight and obese subjects in the present study were free of the cardiovascular and metabolic abnormalitites that often accompany excess body fatness, such as clinically overt coronary artery disease, hypertension, type 2 diabetes, dyslipidemia, and hyperinsulinemia (7). Thus it is tempting to speculate that diminished endothelial t-PA release might be a primary consequence of overweight or obesity. However, in addition to being overweight or obese, the subjects in the present study were sedentary. We (48) have previously demonstrated that a sedentary lifestyle is associated with impaired endothelial release of t-PA. Moreover, epidemiological studies suggest that physical inactivity might contribute significantly to the increased cardiovascular risk with overweight and obesity. Indeed, the prevalence of cardiovascular and metabolic abnormalities has been shown to be lower in overweight and obese adults who engage in regular physical activity (18, 28). The results of our exercise intervention study support this notion and demonstrate that impaired endothelial t-PA release is not an unavoidable consequence of overweight and obesity.

Indeed, 3 mo of moderate aerobic exercise training (primarily walking) resulted in a marked improvement in the capacity of the endothelium to release t-PA in previously sedentary overweight and obese adults. The rate and total amount of t-PA antigen released across the forearm in response to bradykinin increased by >50% after exercise training and, notably, were no longer significantly different from the levels observed in the normal weight controls. It is important to emphasize that the improvement in endothelial t-PA release occurred without concomitant changes in body mass and body composition and was accomplished with a moderate intensity home-based aerobic exercise training program that can be safely performed by most, if not all, overweight and obese adults. The fact that the capacity of the endothelium to release t-PA increased independent of weight loss or changes in body composition and lipid profile suggest a primary modulatory effect of aerobic exercise on endothelial fibrinolytic regulation. Several factors may underlie the exercise-induced increase in endothelial t-PA release capacity, such as shear stress-induced increases in endothelial t-PA mRNA signal expression and protein synthesis (12, 13) and elevated intracellular calcium concentrations facilitating greater t-PA release upon stimulation (29). In addition, we observed no change in CRP, IL-6, IL-18, and TNF-{alpha} with exercise training, further supporting the benign influence of these circulating inflammatory factors on endothelial t-PA release. Importantly, from a public health perspective, our findings emphasize that overweight and obese persons can receive important cardioprotective effects from moderate regular aerobic exercise regardless of changes in adiposity. Improved endothelial fibrinolytic function may be a central mechanism underlying the reduced risk of cardiovascular disease morbidity and mortality observed in overweight and obese adults who engage in regular physical activity (2).

There are two important experimental limitations of the present study that should be mentioned. First, as with all cross-sectional study designs, we cannot rule out the possibility that genetic and/or lifestyle factors might have influenced the results of our group comparisons. In an effort to minimize the influence of lifestyle behaviors, we studied overweight and normal-weight adults of similar age who were nonsmokers, not currently taking medication that could influence endothelial function (i.e., statins), and who did not differ in habitual physical activity. Second, with respect to the exercise intervention, our study design is somewhat weakened by the lack of a nonexercise control group. However, the exercise training program used in the present study has consistently been shown to confer important vascular benefits, such as improvements in central arterial compliance and endothelial vasomotor regulation in healthy middle-aged and older adults (11, 49). Thus it is likely that the observed exercise-induced increase in endothelial t-PA was indeed a primary effect of the intervention.

In conclusion, the results of the present study indicate that the capacity of the endothelium to release t-PA is impaired in middle-aged overweight adults. Endothelial fibrinolytic dysfunction may contribute to the increased risk of atherothrombotic events associated with overweight and obesity. Importantly, impaired endothelial t-PA release is not an irreversible consequence of adiposity. Regular aerobic exercise, independent of weight loss, can significantly enhance endothelial fibrinolytic function in overweight and obese adults. Taken together, our findings support the postulate that regular exercise can alleviate some of the health risks associated with overweight and obesity.


    GRANTS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
This study was supported by National Institutes of Health Grants HL-068030, DK-062061, HL-076434, and MO1 RR-00051, and an American Diabetes Association Clinical Research Award.


    ACKNOWLEDGMENTS
 
We thank all of the subjects who participated in the study, as well as Yoli Casas and Rebecca Keith for technical assistance.


    FOOTNOTES
 

Address for reprint requests and other correspondence: Christopher DeSouza, Dept. of Integrative Physiology, Univ. of Colorado, 354UCB, Boulder, CO 80309 (e-mail: desouzac{at}colorado.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. American Diabetes Association. Clinical practice recommendations 2004. Diabetes Care 27: S1–S150, 2004.
  2. Blair SN and Brodney S. Effects of physical inactivity and obesity on morbidity and mortality: current evidence and research issues. Med Sci Sports Exerc 31: S646–S662, 1999.[CrossRef][ISI][Medline]
  3. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, Evans A, Cambien F, and Tiret L. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 108: 2453–2459, 2003.[Abstract/Free Full Text]
  4. Brommer EJ. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards. Thromb Res 34: 109–115, 1984.[CrossRef][ISI][Medline]
  5. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 11: 1278–1289, 2003.[Abstract/Free Full Text]
  6. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degan J, Bronson R, De Vos R, van den Oord JJ, Collen D, and Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368: 419–424, 1994.[CrossRef][ISI][Medline]
  7. Caterson ID, Hubbard V, Bray GA, Grunstein R, Hansen BC, Hong Y, Labarthe D, Seidell JC, and Smith SC Jr. Prevention Conference VII: Obesity, a worldwide epidemic related to heart diease and stroke: Group III: worldwide comorbidities of obesity. Circulation 110: e476–e483, 2004.[Free Full Text]
  8. Chaplin H and Mollison P. Correction of plasma trapped in the red cell column of hematocrit. Blood 7: 1227–1238, 1952.[Abstract/Free Full Text]
  9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, and Roccella EJ. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289: 2560–2572, 2003.[Abstract/Free Full Text]
  10. Christie PD, Edelberg JM, Picard MH, Foulkes AS, Mamuya W, Weiler-Guettler H, Rubin RH, Gilbert P, and Rosenberg RD. A murine model of myocardial microvascular thrombosis. J Clin Invest 10: 533–539, 1999.
  11. DeSouza CA, Shapiro LF, Clevenger CM, Dinenno FA, Monahan KD, Tanaka H, and Seals DR. Regular aerobic exercise prevents and restores the age-related decline in endothelium-dependent vasodilation in healthy men. Circulation 102: 1351–1357, 2000.[Abstract/Free Full Text]
  12. Diamond SL, Eskin SG, and McIntire LV. Fluid flow stimulates tissue plasminogen secretion by cultured human endothelial cells. Science 243: 1483–1485, 1989.[ISI][Medline]
  13. Diamond SL, Sharefkin JB, Dieffenbach C, Fraiser-Scott K, McIntire LV, and Eskin SG. Tissue plasminogen activator messenger RNA levels increase in cultured human endothelial cells exposed to laminar shear stress. J Cell Physiol 143: 364–371, 1990.[CrossRef][ISI][Medline]
  14. Emeis JJ. The control of t-PA and PAI-1 secretion from the vessel wall. Vasc Med 6: 153–166, 1995.
  15. Engstrom G, Hedblad B, Stavenow L, Jonsson S, Lind P, Janzon L, and Lindgarde F. Incidence of obesity-associated cardiovascular disease is related to inflammation-sensitive plasma proteins: a population based cohort study. Arterioscler Thromb Vasc Biol 24: 1498–1502, 2004.[Abstract/Free Full Text]
  16. Eriksson P, Reynisdottir S, Lonnqvist F, Stemme V, Hamsten A, and Armer P. Adipose tissue secretion of plasminogen activator inhibitor-1 in nonobese and obese individuals. Diabetologia 41: 65–71, 1998.[CrossRef][ISI][Medline]
  17. Farrell SW, Cheng YJ, and Blair SN. Prevalence of the metabolic sydrome across cardiorespiratory fitness levels in women. Obes Res 12: 824–830, 2004.[Abstract/Free Full Text]
  18. Fedder DO, Koro CE, and L'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 105: 152–156, 2002.[Abstract/Free Full Text]
  19. Feng YH and Hart G. In vitro oxidative damage to tissue-type plasminogen activator: a selective modification of the biological functions. Cardiovasc Res 30: 255–261, 1995.[CrossRef][ISI][Medline]
  20. Flegal KM, Carroll MD, Ogden CL, and Johnson CL. Prevalence and trends in obesity among US adults. JAMA 288: 1723–1727, 2003.[CrossRef][ISI]
  21. Fox KA, Robinson AK, Knabb RM, Rosamond TL, Sobel BE, and Bergman SR. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. Circulation 72: 1346–1354, 1985.[Abstract/Free Full Text]
  22. Hoetzer GL, Stauffer BL, Greiner JJ, Casas Y, Smith DT, and DeSouza CA. Influence of oral contraceptive use on endothelial t-PA release in healthy premenopausal women. Am J Physiol Endocrinol Metab 284: E90–E95, 2003.[Abstract/Free Full Text]
  23. Hoetzer GL, Stauffer BL, Irmiger HM, Ng M, Smith DT, and DeSouza CA. Acute and chronic effects of oestrogen on endothelial tissue-type plasminogen activator release in postmenopausal women. J Physiol 551: 721–728, 2003.[Abstract/Free Full Text]
  24. Hoffmeister HM, Jur M, Ruf-Lehman M, Helber U, Heller W, and Seipel L. Endothelial tissue-type plasminogen activator release in coronary heart disease. Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction. J Am Coll Cardiol 31: 547–551, 1998.[Abstract/Free Full Text]
  25. Hrafnkelsdottir T, Wall U, Jern C, and Jern S. Impaired capacity for endogenous fibrinolysis in essential hypertension. Lancet 352: 1597–1598, 1998.[CrossRef][ISI][Medline]
  26. Jern S, Wall U, Bergbrant A, Selin-Sjogren L, and Jern C. Endothelium-dependent vasodilation and tissue-type plasminogen activator release in borderline hypertension. Arterioscler Thromb 17: 3376–3383, 1997.[Abstract/Free Full Text]
  27. Katzmarzyk PT, Church TS, and Blair SN. Cardiorespiratory fitness attenuates the effects of metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 164: 1092–1097, 2004.[Abstract/Free Full Text]
  28. Kooistra T, Schrauwen Y, Artis J, and Emeis JJ. Regulation of endothelial cell t-PA synthesis and release. Int J Hematol 59: 233–255, 1994.[ISI][Medline]
  29. Kugiyama K, Sakamoto T, Misumi I, Sugiyama S, Ohgushi M, Ogawa H, Horiguchi M, and Yasue H. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res 73: 335–343, 1993.[Abstract/Free Full Text]
  30. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, and Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 39: 1044–1048, 1990.[CrossRef][ISI][Medline]
  31. Levine GN, Keaney JF, and Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. JAMA 332: 512–521, 1995.
  32. Lohman TG, Roche AF, and Mortorell R. Arthropometric Standardization Reference Manual. Champaign, IL: Human Kinetics, 1988.
  33. Macko RF, Ameriso SF, Gruber A, Griffin JH, Fernandez JA, Brandt R, Quismorio FP Jr., Weiner JM, and Fisher M. Impairments of the protein C system and fibrinolysis in infection-associated stroke. Stroke 27: 2005–2011, 1996.[Abstract/Free Full Text]
  34. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, and Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419, 1985.[CrossRef][ISI][Medline]
  35. McGill HC, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, and Strong JP. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 105: 2712–2718, 2002.[Abstract/Free Full Text]
  36. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, and Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289: 76–79, 2003.[Abstract/Free Full Text]
  37. Muldowney JA III and Vaughan DE. Tissue-type plasminogen activator release: new frontiers in endothelial function. J Am Coll Cardiol 40: 967–969, 2002.[Free Full Text]
  38. Must A, Spadano J, Coakley EH, Field AE, Colditz G, and Dietz WH. The disease burden associated with overweight and obesity. JAMA 282: 1523–1529, 1999.[Abstract/Free Full Text]
  39. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, MD: National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases, 1998.
  40. Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KA, Boon NA, and Webb DJ. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 99: 1411–1415, 1999.[Abstract/Free Full Text]
  41. Parmer RJ, Mahata M, Mahata S, Sebald MT, O'Connor DT, and Miles LA. Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. J Biol Chem 272: 1976–1982, 1997.[Abstract/Free Full Text]
  42. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, and Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499–511, 2003.[Free Full Text]
  43. Perticone F, Ceravolo R, Candigliota M, Ventura G, Iacopino S, Sinopoli F, and Mattioli PL. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 50: 159–165, 2001.[Abstract/Free Full Text]
  44. Quyyumi AA. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 105: 32S–39S, 1998.[CrossRef][Medline]
  45. Rea TD, heckbert SR, Kaplan RC, Psaty BM, Smith NL, Lemaitre RN, and Lin D. Body mass index and the risk of recurrent coronary events following acute myocardial infarction. Am J Cardiol 88: 467–472, 2001.[CrossRef][ISI][Medline]
  46. Rosito GA, D'Agostino RB, Massaro J, Lipinska I, Mittleman MA, Sutherland P, Wilson PW, Levy D, Muller JE, and Tofler GH. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 91: 683–689, 2004.[ISI][Medline]
  47. Smith DT, Hoetzer GL, Greiner JJ, Stauffer BL, and DeSouza CA. Effects of ageing and regular aerobic exercise on endothelial fibrinolytic capacity in humans. J Physiol 546: 289–298, 2003.[Abstract/Free Full Text]
  48. Tanaka H, Dinenno FA, Monahan KD, Clevenger CM, DeSouza CA, and Seals DR. Aging, habitual exercise and dynamic arterial compliance. Circulation 102: 1270–1275, 2000.[Abstract/Free Full Text]
  49. Van den Eijnden-Schrauwen Y, Kooistra T, de Vries RE, and Emeis JJ. Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vitro: evidence for a dynamic storage pool. Blood 85: 3510–3517, 1995.[Abstract/Free Full Text]
  50. Walker SP, Rimm EB, Ascherio A, Kawachi I, Stampfer MJ, and Willet WC. Body size and fat distribution as predictors of stroke among US men. Am J Epidemiol 144: 1143–1150, 1996.[Abstract]
  51. Willerson JT and Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 109, Suppl I: II2–II10, 2004.
  52. Williams IL, Wheatcroft SB, Shah AM, and Kearney MT. Obesity, atherosclerosis and vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obes 26: 754–764, 2002.[CrossRef][ISI]